|
��չ����
|
|
| ������Ϣ | |
 |
Supporting info |
|
PDFȫ�� |
|
[HTMLȫ��] |
|
����� |
| �����뷴�� | |
|
�������ù����� |
|
���� |
|
Email Alert |
|
���·��� |
|
���������Ϣ |
| ���Ĺؼ���������� | |
|
�������,rex |
|
Ƥ������ |
|
ϸ�����ڵ��� |
| ��������������� | |
|
�￭Ӣ |
|
���� |
| PubMed | |
|
Article by |
|
Article by |
p27��Ƥ������
�￭Ӣ, ����
�㽭��ѧҽѧԺ������һҽԺƤ����, ����310003
p27��ϸ�����������Լ�ø�������Ӽ����е�һԱ,��Ҫ����ϸ�����ڵĸ��Ե��ء��� ��ϸ����ֳ�յ�ϸ���ֻ����ٽ�ϸ������,�Ƕ������������ƻ�������p27��Ƥ����������Ƥ�� ��״ϸ������Kaposi�������ǻ���Ƥ���ȶ���Ƥ�������Ĺ�ϵ��
[2] Harvat BL, Seth P, Jetten AM. The role of p27Kipl in gamma interferon-mediated growth arrest of mammary epithelial cells and related defects in mammary carcinoma cells. Oncogene, 1997, 14:2111-2122.
[3] Kuzumaki T, Kobayashi T, Ishikawa K. Genistein induces p21 (Cipl/WAF1) expression and blocks the G1 to S phase transition in mouse fibroblast and melanoma cells. Biochem Biophys Res Commun, 1998, 251:291-295.
[4] Moon J, Yu SJ, Kim HS, et al. Induction of G(1) cell cycle arrest and p27 (KIP1) increase by panaxydol isolated from Panax ginseng.Biochem Pharmacol, 2000, 59:1109.
[5] Durand B, Gao FB, Raff M. Accumulation of the cyclin-dependent kinase inhibitor p27/Kipl and the timing of oligodendrocyte differentiation. EMBO J, 1997, 16:306-317.
[6] Fujieda S, Inuzuka M, Tanaka N, et al. Expression of p27 is associated with Bax expression and spontaneous apoptosis in oral and oropharyngeal carcinoma. Int J Cancer, 1999, 84:315-320.
[7] Kawamata N, Morosetti R, Miller CW, et al. Molecular analysis of the cyclin-dependent kinase inhibitor gene p27/Kipl in human malignancies. Cancer Res, 1995, 55:2266.
[8] Lloyd RV, Jin L, Qian X, et al. Aberrant p27kipl expression in endocrine and other tumors. Am J Pathol, 1997, 150:401-407.
[9] Mayr B, Wilhelm B, Reifinger M, et al. Absence of p21 WAF1 and p27 kipl gene mutations in various feline tumours. Vet Res Commun,2000, 24:115-124.
[10] Ophaseharoensuk V, Fero ML, Hughes J, et al. The cyclin-dependent kinase inhibitor p27Kipl safeguards against inflammatory injury.Nat Med, 1998, 4:575-580.
[11] Haddad MM, Xu W, Medrano EE. Aging in epidermal melanocytes:cell cycle genes and melanins. J Investig Dermatol Symp Proc, 1998,3:36-40.
[12] Haddad MM, Xu W, Schwahn DJ, et al. Activation of a cAMP pathway and induction of melanogenesis correlate with association of p16 (INK4) and p27 (KIP1) to CDKs, loss of E2F-binding activity, and premature senescence of human melanocytes. Exp Cell Res, 1999,253:561-572.
[13] Bales ES, Dietrich C, Bandyopadhyay D, et al. High levels of expression of p27KIP1 and cyclin E in invasive primary malignant melanomas. J Invest Dermatol, 1999, 113:1039.
[14] Yao J, Eu KW, Seow-Choen F, et al. Down-regulation of p27 is a significant predictor of poor overall survival and may facilitate metastasis in colorectal carcinomas. Int J Cancer, 2000, 89:213-216.
[15] D'Aguano I, Valentini A, Fornari C, et al. Myc down-regulation induces apoptosis in M14 melanoma cells by increasing p27 (kipl) levels. Oncogene, 2001,20:2814-2825.
[16] Morgan MB, Cowper SE. Expression of p-27 (kipl) in nevi and melanomas. Am J Dermatopathol, 1999, 21:121.
[17] Shiozawa T, Shiohara S, Kanai M, et al. Expression of the cell cycle regulator p27 (Kipl) in normal squamous epithelium, cervical intraepithelial neoplasia, and invasive squamous cell carcinoma of the uterine cervix. Immunohistochemistry and functional aspects of p27 (Kipl). Cancer, 2001,92:3005-3011.
[18] Bayazit YA, Karakok M, Ucak B, et al. Cycline-dependent kinase inhibitor, p27 (KIP1), is associated with cholesteatoma. Laryngoscope, 2001, 111:1037-1041.
[19] Oka K, Suzuki Y, Nakano T. Expression of p27 and p53 in cervical squamous cell carcinoma patients treated with radiotherapy alone:radiotherapoutic effect and prognosis. Cancer, 2000, 88:2766-2773.
[20] Koh TY, Park SW, Park KH, et al. Inhibitory effect of p27KIP1 gene transfer on head and neck squamous cell carcinoma cell lines. Head Neck, 2003, 25:44-49.
[21] Hwang CF, Su CY, Huang SC, et al. Low expression levels of p27 correlate with loco-regional recurrence in nasopharyngeal carcinoma.Cancer Lett, 2003, 189:231-236.
[22] Mineta H, Miura K, Suzuki I, et al. Low p27 expression correlates with poor prognosis for patients with oral tongue squamous cell carcinoma. Cancer, 1999, 85:1011-1017.
[23] Fernandez-Figueras MT, Puig L, Penin RM, et al. Decreased immunoreactivity for cell-cycle regulator p27 (Kipl) in Kaposi's sarcoma correlates with higher stage and extracutaneous involvement. J Pathol,2000, 191:387-393.
[24] Cotran RS, Kumar V, Collins T. Disease of immunity. In:Cotran RS, Kumar V, eds. Pathologic Basis of Disease. 6th ed. Philadelphia:Saunders, 1999,248-249.
[25] Hu W, CooR T, Oh CW, et al. Expression of the cyclin-dependent kinase inhibitor p27 in keratoacanthoma. J Am Acad Dermatol, 2000,42:473-475.